The power of liquid biopsy combined with a multi-algorithmic approach
We’re detecting cancer through a single blood draw instead of an invasive tissue biopsy. Our liquid biopsy approach combines low-pass whole genome sequencing (LP-WGS) with proprietary machine learning techniques. Using Deep Learning, we've trained our algorithm using thousands of samples from healthy individuals and cancer patients. The algorithm analyzes 30,000 unique genetic features in each sample and derives a genetic signature that can be used to accurately detect the presence of circulating tumor DNA in the sample.
Learn More
Critical cancer detection for early intervention
We’re taking aim at cancer screening and detection in areas of acute need, with a focus on women's health and high-mortality cancers. Our high-complexity, CLIA-certified/CAP-accredited lab advances screening and detection methods for many of the most pervasive cancers.
Explore Now
Tailoring AI towards a deadly disease
Located in the heart of the biotech corridor in San Diego, Genece is focused on using AI to positively impact the future of cancer detection.
We’re bringing disruptive technology to the U.S. by forming a strategic partnership with GC Genome and GC Corporation, South Korea’s largest life sciences company.
About Us